Biotech Startups

Everlife-Research Instruments supplies research tools, laboratory equipment, and analytical solutions to the scientific and clinical community in Asia. The company provides a full range of services from product distribution to technical support, regulatory guidance, and laboratory design.

1 investor

Reservoir Neuroscience is developing therapeutics aimed at repairing the blood-brain barrier. The company operates in the neuroscience drug development space.

1 investor

Resilient Medical Corp designs an implantable device, Bravo, placed during breast cancer lumpectomy surgery to support tissue healing, avoid follow-up cosmetic reconstruction, and act as a radiocontrast marker for post-operative therapy. The company targets breast cancer surgical patients and clinicians in the medical device industry.

1 investor

ResNovas Therapeutics appears to be a therapeutics company, but the page provides no usable details about its products, technology, or market.

1 investor

Resolian is a Contract Research Organization (CRO) that provides bioanalytical, biomarker, and analytical sciences services to support drug development for pharma and biotech companies. The company specializes in GxP and non-regulated bioanalysis, drug metabolism and pharmacokinetic services, and GMP CMC analytical and materials science across all therapeutic modalities.

1 investor

Resolution develops a macrophage cell therapy to treat end-stage liver disease, aiming to reduce the need for liver transplantation and improve patient outcomes. The company focuses on regenerative medicine for inflammatory and fibrotic diseases.

1 investor

Resolve Nanotherapeutics is developing RNA drugs delivered via lipid nanoparticles that amplify the body's toxin-clearance pathway to treat severe acute bacterial infections and their chronic complications. Its host-focused therapy targets the immune system rather than the bacteria, aiming to work against antibiotic-resistant infections in critical care settings.

1 investor

Response Bio develops the RAMP platform, which delivers acute care diagnostic testing with lab-quality results within minutes to support rapid clinical decision-making in healthcare settings. The company serves medical teams and partners seeking to reduce diagnostic turnaround time and total cost of care.

1 investor

Response Pharmaceuticals is a clinical-stage drug developer working on RDX-002, a small-molecule iMTP inhibitor for weight management and metabolic health, including post-GLP-1 receptor agonist weight management and antipsychotic-induced weight gain. The company is advancing the candidate through Phase 2 clinical trials.

1 investor

ResQ Pharma is a pharmaceutical company developing LipidRescue (LRT), an investigational lipid-based drug therapy that is pending FDA approval. The company works on biologics development, regulatory affairs, and clinical research for its drug candidate.

1 investor

Reticular provides genetic screening and embryo analysis for prospective parents, offering risk assessments for pregnancy loss, inherited diseases, and health traits to inform reproductive decisions.

1 investor

RetMap develops next-generation electroretinography sensors and diagnostic medical devices for screening, diagnosis, and treatment of neurodegenerative eye conditions. The company serves ophthalmologists and clinicians seeking to detect and manage retinal diseases and prevent vision loss.

1 investor

RevMed is an advanced regenerative medicine company focused on researching and developing therapeutic solutions in the regenerative medicine field. The company aims to extend human lifespan and improve health outcomes through life-centered innovation.

1 investor

Revadix develops first-in-class small molecule therapies targeting the EPAC1 signalling pathway to treat atrial fibrillation, addressing the underlying disease mechanism rather than symptoms. Its lead asset AM-001 is entering IND-enabling studies while a second EPAC1-targeting program is in lead optimization, aimed at cardiac arrhythmia patients.

1 investor

Revagenix is a precision-therapeutics company that develops drugs for serious chronic diseases, starting from the underlying biology and unmet clinical needs. Its lead program, Rev-56, is an inhaled therapy with a novel mechanism of action designed for non-CF bronchiectasis (NCFB).

1 investor

REVA Medical develops bioresorbable polymers for medical implants, with a focus on vascular applications. The company creates drug-eluting bioresorbable scaffolds for treating coronary artery disease, positioned as an alternative to permanent metallic stents.

1 investor

Revascular Bio develops cell therapy treatments using vascular endothelial stem cells to address diseases caused by vascular dysfunction, including chronic wounds, severe limb ischemia, and genetic blood disorders. The company targets intractable diseases with angiogenic therapy, angiocrine therapy, and protein production platforms.

1 investor

Revelio Therapeutics is a biotechnology company developing tumor-specific biologic drugs for cancer treatment.

1 investor

Revilico builds an operating system for pharmaceutical R&D that unifies computational drug discovery tools—including molecular dynamics, quantum chemistry, generative chemistry, and virtual cell simulations—with integrated wet-lab validation. The platform serves pharmaceutical researchers and biotech companies developing small molecule drugs, covering all phases from target identification through lead optimization and preclinical development.

1 investor

Reviva Pharmaceuticals is a clinical-stage drug developer with a pipeline of two in-house-discovered new chemical entities, brilaroxazine (RP5063) and RP1208, developed using its chemical genomics platform. Its lead candidate, brilaroxazine, is being developed for schizophrenia and has completed a Phase 3 trial.

1 investor

RreviveMed applies artificial intelligence to metabolomics and biology to support drug discovery in the pharmaceutical and biotech sector.

1 investor

Revolver Therapeutics develops peptide therapeutics targeting transcription factors for cancer treatment. It uses a proprietary peptide discovery and screening platform to screen millions of peptides and identify functional inhibitors.

1 investor

Rhapsogen is developing a precision biologic therapy aimed at treating autoimmune diseases, focused on efficacy, safety, and durability.

1 investor

RheaPlant develops a plant cell bioprocessing platform designed to reduce the cost and complexity of producing botanical ingredients for nutraceuticals, natural colors, and other applications. The modular, decentralized system targets ingredient manufacturers seeking lower-cost alternatives to traditional botanical extraction and cultivation methods.

1 investor